/nginx/o/2020/12/28/13550349t1h695c.jpg?fit=%2C&ssl=1)
According to the European Union’s ongoing safety monitoring plan for Covid-19 vaccines, monitoring of these vaccines will be significantly intensified than for other medicinal products to ensure the rapid identification, compilation and analysis of new safety information. These measures also allow regulatory authorities to quickly assess the latest data from various sources and, if necessary, take all necessary regulatory action to protect public health.
–
Any report of adverse reactions to Covid-19 vaccines is carefully considered. The reports are evaluated by the Latvian State Agency of Medicines, in difficult cases also involving the State Council of Immunization, the Health Inspectorate and other specialists, as well as specialists from EZA, as well as drug agencies from all European countries.
–
The most common reports in Latvia are mainly known reactions and side effects reported in the vaccine package leaflet and in the SPCs, such as injection site reactions, fever, chills and fatigue. According to the reports, these side effects disappeared within one to two days. Similar vaccine-induced reactions have been reported with other vaccines.
–
The MAH emphasizes that as with all vaccines and any medicinal product, such reactions or side effects may occur after administration of Covid-19 vaccines. According to the reports, vaccines developed by Pfizer / BioNTech and Moderna tend to have more severe side effects after the second dose of the vaccine. In contrast, for AstraZeneca, they tend to be more pronounced after the first dose. For all vaccines, side effects occur most often in the first few days after vaccination, last for a few days and then disappear rapidly. They are usually less pronounced in the elderly.
–
The MAH reminds that if, after receiving a dose of the vaccine, expected but severe or other reactions of the body, which significantly reduce the ability to work, are observed, a doctor should be consulted, who may decide to award a certificate of incapacity for work.
–
In this regard, Saeima deputy Vitalijs Orlovs (S) also previously informed LETA that his acquaintance had been vaccinated with the ABV5300 series vaccine on March 5. The vaccinators arrived on a trip to a particular company around 2 pm and on the same day the vaccination of the company’s employees took place later.
–
The next day, March 6, a person of retirement age who had received a series of pots, his health had deteriorated, and his health had also deteriorated on Sunday, March 7, and on Monday, March 8, his deputy’s acquaintance passed away, Orlov said.
–
The politician states that he understands that this case is about a 70-year-old person who has suffered from some diseases. At one time, an eternal acquaintance was active in his work, the parliamentarian drew attention.
–
The deputy emphasized that a person of retirement age had been vaccinated with the vaccine of this series “ABV5300”, about which on March 9 the state representatives informed that the use of vaccines of this series is temporarily suspended.
–
LETA reported that on March 9, information was received that, as an additional precaution, the Health Inspectorate (MA) and the State Agency of Medicines had temporarily suspended the use of one batch of AstraZeneca vaccine. The MA and the MAH have been informed that the Austrian national competent pharmacovigilance authority has suspended the use of one batch of Covid-19 vaccine developed by AstraZeneca under the serial number “ABV5300”.
— .
/cloudfront-us-east-1.images.arcpublishing.com/lanacionar/AI7FPEO7SVDTVBECT3E3SUM33M.jpg?resize=150%2C150&ssl=1)
